Literature DB >> 25743716

Response to Bodini et al.

S Paul1, X Roblin2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25743716     DOI： 10.1038/ajg.2015.12

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  8 in total

1.  Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice.

Authors:  Giorgia Bodini; Edoardo G Giannini; Edoardo V Savarino; Vincenzo Savarino
Journal:  Am J Gastroenterol       Date:  2015-03       Impact factor: 10.864

2.  Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

Authors:  N Vande Casteele; D J Buurman; M G G Sturkenboom; J H Kleibeuker; S Vermeire; T Rispens; D van der Kleij; A Gils; G Dijkstra
Journal:  Aliment Pharmacol Ther       Date:  2012-08-28       Impact factor: 8.171

3.  A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

4.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

Authors:  Xavier Roblin; Hubert Marotte; Melanie Rinaudo; Emilie Del Tedesco; Amelie Moreau; Jean Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Stephane Paul
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

5.  Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Authors:  Xavier Roblin; M Rinaudo; E Del Tedesco; J M Phelip; C Genin; L Peyrin-Biroulet; S Paul
Journal:  Am J Gastroenterol       Date:  2014-06-10       Impact factor: 10.864

6.  Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.

Authors:  Hirotsugu Imaeda; Kenichiro Takahashi; Takehide Fujimoto; Shigeki Bamba; Tomoyuki Tsujikawa; Masaya Sasaki; Yoshihide Fujiyama; Akira Andoh
Journal:  J Gastroenterol       Date:  2013-04-11       Impact factor: 7.527

Review 7.  Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.

Authors:  Stephane Paul; Amelie Carla Moreau; Emilie Del Tedesco; Melanie Rinaudo; Jean-Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Xavier Roblin
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

8.  Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization.

Authors:  Ann Gils; Niels Vande Casteele; Raf Poppe; Marlies Van de Wouwer; Griet Compernolle; Miet Peeters; Els Brouwers; Séverine Vermeire; Nick Geukens; Paul J Declerck
Journal:  Ther Drug Monit       Date:  2014-10       Impact factor: 3.681
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.